[New smoking cessation preparations unsuitable in mental disorders].
D001552:Benzazepines / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000150:complications / Q000188:drug therapy; D016642:Bupropion / Q000009:adverse effects*; D000075202:Contraindications; D018765:Dopamine Uptake Inhibitors / Q000009:adverse effects; D006801:Humans; D011810:Quinoxalines / Q000009:adverse effects*; D011978:Receptors, Nicotinic / Q000187:drug effects; D012307:Risk Factors; D016540:Smoking Cessation; D000068580:Varenicline
D001552:Benzazepines; D018765:Dopamine Uptake Inhibitors; D011810:Quinoxalines; D011978:Receptors, Nicotinic; D016642:Bupropion; D000068580:Varenicline